Bullish option flow detected in BridgeBio Pharma with 2,899 calls trading, 1.7x expected, and implied vol increasing over 2 points to 58.60%. Jan-25 30 calls and Jan-25 35 calls are the most active options, with total volume in those strikes near 1,800 contracts. The Put/Call Ratio is 0.01. Earnings are expected on October 31st.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio presenting results of Phase 3 study of acoramidis in ATTR-CM
- BridgeBio initiated with a Perform at Oppenheimer
- BridgeBio completes enrollment of FORTIFY Phase 3 study of BBP-418
- Opening Day: Obesity drug developer BioAge makes Nasdaq debut
- BridgeBio presents post-hoc analysis evaluating acoramidis